Three days after electrode implantation, baseline seizure activity was determined over 3 days. Thereafter, perampanel (2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile, a non-competitive AMPAR antagonist; 8 mg/kg, i.p, Eisai Korea Inc., Seoul, South Korea), GYKI 52,466 (a non-competitive AMPAR inhibitor, 10 mg/kg, i.p.) or saline (vehicle) was daily administered at a certain time of the day (PM 6:00) over a 1-week period [9 (link),54 (link)]. On the basis of previous studies [55 (link),56 (link)], some animals were also given BpV(pic) (2 mg/kg, i.p.) with perampanel or GYKI 52466. EEG was recorded 2 h a day at the same time over a 1-week period. EEG signals were recorded with a DAM 80 differential amplifier (0.1–3000 Hz bandpass; World Precision Instruments, Sarasota, FL, United States) and the data were digitized (1000 Hz) and analyzed using LabChart Pro v7 (ADInstruments, Bella Vista, New South Wales, Australia). Behavioral seizure severity was also evaluated as aforementioned. After recording (18 h after the last treatment), animals were used for Western blot and immunohistochemical study.
Free full text: Click here
